
Biomedical Materials Market in China
China biomedical materials market by material type (metals, polymers, others), by application (cardiovascular diseases, orthopaedics, plastic surgery, others), industry snapshot, 2023-2029
Global axial spondyloarthritis (axSpA) market by commercialized therapies (anti-tumor necrosis factor therapy, anti-interleukin 17 therapy, anti-janus kinase therapy), by indication (ankylosing spondylitis, non-radiographic axial spondyloarthritis (nr-axSpA)), by region (North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America), outlook & forecast, 2023-2029
Axial spondyloarthritis (axSpA) is a type of inflammatory arthritis that primarily affects the spine, but it can also affect other joints and organs such as the eyes, skin, and gut. It is a chronic condition that can cause pain, stiffness, and loss of mobility. Early diagnosis and treatment of axial spondyloarthritis are essential to control the symptoms and prevent complications. While there is no cure for axial spondyloarthritis, effective treatment can help manage the symptoms and improve quality of life. The global axial spondyloarthritis market size is projected to grow by USD 1.2 billion from 2023 to 2029, registering a CAGR of 7.84 percent, according to the latest market data.
The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global axial spondyloarthritis market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the commercialized therapies, indication, and region. The global market for axial spondyloarthritis can be segmented by commercialized therapies: anti-tumor necrosis factor therapy, anti-interleukin 17 therapy, anti-janus kinase therapy. Globally, the anti-tumor necrosis factor therapy segment made up the largest share of the axial spondyloarthritis market. Axial spondyloarthritis market is further segmented by indication: ankylosing spondylitis, non-radiographic axial spondyloarthritis (nr-axSpA). The ankylosing spondylitis segment captured the largest share of the market in 2022. Based on region, the axial spondyloarthritis market is segmented into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. According to the research, North America had the largest share in the global axial spondyloarthritis market.
Market Segmentation
By commercialized therapies: anti-tumor necrosis factor therapy, anti-interleukin 17 therapy, anti-janus kinase therapy
By indication: ankylosing spondylitis, non-radiographic axial spondyloarthritis (nr-axSpA)
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America
The global axial spondyloarthritis market report offers detailed information on several market vendors, including Pfizer Inc., Johnson & Johnson Services, Inc., Novartis International AG, UCB S.A., Eli Lilly and Company, Kyowa Kirin Co., Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Amgen Inc., Merck & Co., Inc., Takeda Pharmaceutical Company Limited, among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
Scope of the Report
• To analyze and forecast the market size of the global axial spondyloarthritis market.
• To classify and forecast the global axial spondyloarthritis market based on commercialized therapies, indication, region.
• To identify drivers and challenges for the global axial spondyloarthritis market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global axial spondyloarthritis market.
• To identify and analyze the profile of leading players operating in the global axial spondyloarthritis market.
Why Choose This Report
• Gain a reliable outlook of the global axial spondyloarthritis market forecasts from 2023 to 2029 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.
PART 1. INTRODUCTION
Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience
PART 2. METHODOLOGY
PART 3. EXECUTIVE SUMMARY
PART 4. MARKET OVERVIEW
Introduction
Drivers
Restraints
PART 5. MARKET BREAKDOWN BY COMMERCIALIZED THERAPIES
Anti-tumor necrosis factor therapy
Anti-interleukin 17 therapy
Anti-janus kinase therapy
PART 6. MARKET BREAKDOWN BY INDICATION
Ankylosing spondylitis
Non-radiographic axial spondyloarthritis (nr-axSpA)
PART 7. MARKET BREAKDOWN BY REGION
North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America
PART 8. KEY COMPANIES
Pfizer Inc.
Johnson & Johnson Services, Inc.
Novartis International AG
UCB S.A.
Eli Lilly and Company
Kyowa Kirin Co., Ltd.
Bristol-Myers Squibb Company
AbbVie Inc.
Amgen Inc.
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
DISCLAIMER
Pfizer Inc.
Johnson & Johnson Services, Inc.
Novartis International AG
UCB S.A.
Eli Lilly and Company
Kyowa Kirin Co., Ltd.
Bristol-Myers Squibb Company
AbbVie Inc.
Amgen Inc.
Merck & Co., Inc.
Takeda Pharmaceutical Company Limited
China biomedical materials market by material type (metals, polymers, others), by application (cardiovascular diseases, orthopaedics, plastic surgery, others), industry snapshot, 2023-2029
Global heart tumor market by tumor type (primary tumor, secondary tumor), by type (diagnosis, treatment), by region (North America, Europe, Asia-Pacific, Rest of the World (RoW)), outlook & forecast, 2023-2029
Global therapeutic contact lenses market by material (soft, rigid), by usage (daily displacement, frequent replacement), by distribution (omni channel, hospitals and eye care clinics), by application (post ocular surgery, corneal surgery/disorder, drug delivery, others), by region (North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America), outlook & forecast, 2023-2029
Please fill out our form and we will get back to you.